source
- Johnson & Johnson prepares $2.58 billion option to acquire Sail Biomedicines, expanding in-vivo CAR-T portfolioJohnson & Johnson announced a $2.58 billion option agreement to purchase Sail Biomedicines, a Flagship Pioneering‑backed biotech focused on in‑vivo CAR‑T therapies. The deal includes an upfront pa…
- BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearBMS may have been absent from the dealmaking spree of some of its Big Pharma peers this year, but that might not change anytime soon.Fierce Biotech · 12h ago↗ source